Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Outbreak of life-threatening coagulopathy associated with synthetic cannabinoids use

December 14, 2018

The Centers for Disease Control and Prevention (CDC) has provided information on a multistate outbreak of coagulopathy from exposure to synthetic cannabinoids products containing a vitamin K-epoxide cycle antagonist, brodifacoum. To learn more about this outbreak, and what you can do to help your patients who may be affected by it, please refer to the CDC?s alert.

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.